Format

Send to

Choose Destination
Clin Breast Cancer. 2014 Aug;14(4):258-64. doi: 10.1016/j.clbc.2013.10.019. Epub 2013 Oct 26.

Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.

Author information

1
Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: alessandra.balduzzi@ieo.it.
2
Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Department of Statistics and Quantitative Methods, Unit of Biostatistics, Epidemiology and Public Health, University of Milan-Bicocca, Milan, Italy.
3
Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.
4
Division of Medical Senology, European Institute of Oncology, Milan, Italy.
5
Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy; School of Medicine, University of Milan, Italy.
6
School of Medicine, University of Milan, Italy; Molecular Senology Unit, European Institute of Oncology, Milan, Italy.
7
Division of Senology, European Institute of Oncology, Milan, Italy.
8
Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy.
9
Vice-Scientific Director, European Institute of Oncology, Milan, Italy.

Abstract

INTRODUCTION:

The prognostic value of low estrogen and progesterone receptors expression (ER/PgR 1%-10%) in early breast cancer patients is still unclear.

PATIENTS AND METHODS:

We retrospectively analyzed 1424 consecutive patients with HER2/neu-negative and low endocrine receptors expression early breast cancer, submitted to surgery at the European Institute of Oncology between January 1995 and December 2009. Patients were classified according to the percentage of ER/PgR expression using immunohistochemistry. Group 1 with ER/PgR < 1%, and group 2 with ER/PgR 1% to 10%.

RESULTS:

Group 1 (ER/PgR < 1%) included 1300 patients, and group 2 (ER/PgR 1%-10%) 124 patients. Median follow-up time was 74 months (range, 3-192 months). The 5-year disease-free survival (DFS) rate was 74% (95% confidence interval [CI], 72%-77%) for group 1, and 79% (95% CI, 70%-86%) for group 2 (P = .16). The 5-year overall survival (OS) rate was 86% (95% CI, 84%-88%) in group 1 and 90% (95% CI, 83%-95%) in group 2 (P = .13). In patients without lymph node involvement, the 5-year OS rate was 92% (95% CI, 89.5%-93.6%) for group 1 and 98% (95% CI, 90.2%-99.8%) for group 2 (P = .061). One hundred ten patients received endocrine therapy with no significant effect on DFS (P = .36) and OS (P = .30).

CONCLUSION:

The ER/PgR 1%-10% group had a slight, but not statistically significant, better prognosis than the ER/PgR <1% group. Further studies are needed to identify the appropriate clinical approach in this subset of patients with low ER/PgR expression (ER/PgR 1%-10%), HER2-negative early breast cancer.

KEYWORDS:

Adjuvant treatment; Estrogen receptor; Histologic subtypes; Low endocrine responsiveness; Overall survival

PMID:
24325948
DOI:
10.1016/j.clbc.2013.10.019
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center